Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Effectiveness of Efgartigimod in Acetylcholine Receptor-positive Generalized Myasthenia Gravis
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (11:45 AM-12:45 PM)
11-014
Intravenous efgartigimod is a neonatal Fc receptor antagonist developed for use in generalized myasthenia gravis. There is currently limited data characterizing the real-world application of efgartigimod since its approval in the US in December 2021. 

The purpose of this study is to describe the clinical experience, including effectiveness and side effects, of intravenous efgartigimod use in 11 patients with acetylcholine receptor-positive generalized myasthenia gravis (AChR +ve gMG).

This is a retrospective chart review of 11 AChR +ve gMG patients who were treated with at least 2 cycles of IV efgartigimod and had both pre- and post- efgartigimod myasthenia gravis activities of daily living (MG-ADL) scores. Information regarding patient demographics, concomitant treatment(s), MG clinical history, and adverse events was reported. An improvement in MG-ADL of 2 or more was considered clinically meaningful.

A total of 11 patients (M:5, F:6) with a mean age of 57.36 (± 18.72) were included in this cohort. A total of 73% (8/11) of patients had a clinically meaningful reduction (≥ 2-point change) in MG-ADL after completion of the first cycle of efgartigimod. Eighty-two percent (9/11) had a clinically meaningful reduction in MG-ADL after cycle 2 (mean pre-efgartigimod 9.27 [± 1.62] versus post-efgartigimod 6.1 [±2.33]). One patient achieved minimal symptom expression after cycle 2. In 3 patients, prednisone dose (mean pre-efgartigimod dose 25.91 mg [±5.39]) was tapered after cycle 2 (mean dose reduction 6.67 [±2.89]). Side effects were mild with one patient experiencing headache and one upper respiratory infection.

Efgartigimod led to clinically meaningful improvement in MG-ADL in 82% of AChR +ve gMG patients after two cycles with mild side effects. Prednisone dose was reduced in 3/11 patients by an average of 6.67 (±2.89).

Authors/Disclosures
Alexis King (A.T. Still University - SOMA)
PRESENTER
Mrs. King has nothing to disclose.
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.